VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to ...

The US Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies ...

The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...